Product Serialization & Tracking (DSCSA)

1. What is the primary purpose of the Drug Supply Chain Security Act (DSCSA)?

DSCSA's core purpose is establishing electronic traceability across the pharmaceutical supply chain to detect and remove counterfeit, stolen, or otherwise illegitimate product. It does not govern licensing exams (A), pricing (B), or REMS determinations (D), which are separate regulatory frameworks.

2. What four elements make up the product identifier required under DSCSA, typically encoded in a 2D barcode on drug packaging?

The DSCSA product identifier consists of the NDC, a unique serial number, the lot number, and the expiration date, typically encoded in a 2B data matrix barcode. The other options list irrelevant or incorrect data elements that are not part of the product identifier.

3. Under DSCSA, what must trading partners, such as manufacturers, wholesalers, and dispensers, verify about each other before engaging in transactions?

DSCSA requires trading partners to confirm one another's status as authorized trading partners with appropriate licensure or registration before transacting, helping keep illegitimate actors out of the supply chain. Revenue (A), shipping carrier preference (C), and marketing budget (B) are irrelevant to this verification requirement.

4. A pharmacy technician receives a shipment and notices packaging that appears tampered with and inconsistent with the expected product identifier. What term describes this product's status while it is being investigated?

Product that may be counterfeit, diverted, or otherwise unfit based on available information, before confirmation, is termed suspect product and must be quarantined and investigated. Illegitimate product (A) is the term used once the investigation confirms the product is not legitimate. Grandfathered product (C) and saleable return (D) refer to unrelated DSCSA concepts.

5. Once a product is confirmed to be illegitimate under DSCSA, what must the pharmacy do regarding notification?

Once product is confirmed illegitimate, DSCSA requires quarantine plus notification to the FDA and relevant trading partners within 24 hours. Simply destroying without notification (A) skips a required regulatory step, waiting for routine inventory (C) is far too slow for this safety issue, and notifying only the patient (B) omits the required regulatory notifications.

6. Which older federal law did DSCSA largely replace and update regarding wholesale drug distribution pedigree requirements?

DSCSA updated and largely superseded the older paper-pedigree requirements established under the Prescription Drug Marketing Act. CMEA (A) concerns pseudoephedrine, the CSA (C) governs controlled substance scheduling generally, and the Hatch-Waxman Act (D) concerns generic drug approval and patent issues, none of which is the pedigree law DSCSA replaced.

7. When a pharmacy returns unopened, unexpired product to a wholesaler for credit, known as a saleable return, what does DSCSA require before the wholesaler can resell it?

DSCSA requires package-level verification of the product identifier for saleable returns before a wholesaler can return the product to sellable inventory, ensuring authenticity. A skips this required safeguard, B misdescribes the saleable return process, which allows resale rather than mandating destruction, and D incorrectly excludes wholesalers from performing this verification.

8. What is a pharmacy technician's practical role in supporting DSCSA compliance when receiving a drug shipment?

Technicians commonly help verify DSCSA product identifiers via barcode scanning during receiving and flag discrepancies for pharmacist review. Contacting the FDA directly for every shipment (B) is not the routine process, filing Form 222 for all shipments (C) applies only to Schedule I and II ordering, not general DSCSA compliance, and determining DEA schedules (D) is unrelated to DSCSA identifier verification.

9. What does the term grandfathered product mean under DSCSA?

Grandfathered DSCSA product refers to inventory that entered commerce before applicable serialization requirements took effect, exempting it from needing the newer product identifier. It is unrelated to a recall (B), donation status (C), or expired product still on shelf (D), which are separate concepts entirely.

10. Under DSCSA, is a patient who receives a dispensed prescription for personal use considered a trading partner in the drug supply chain?

DSCSA's trading partner framework governs manufacturers, wholesalers, repackagers, and dispensers; a patient receiving a dispensed medication for personal use is outside that framework since the chain of custody ends at dispensing. A and C mischaracterize patients as trading partners, and D describes an illegal resale scenario, not a recognized DSCSA classification.

1. Besides authenticating the product, what practical benefit does the lot number and expiration date within the DSCSA product identifier provide?

Beyond enabling traceability, the lot number and expiration date embedded in the product identifier support recall management and expiration tracking. These elements do not determine DEA schedule (B) or set pricing (C), and they supplement, rather than replace, the NDC (D).

2. Prior to full interoperable, unit-level electronic tracing, DSCSA required trading partners to pass along which three types of transaction documentation with each change of ownership?

During DSCSA's phased implementation, trading partners exchanged Transaction History, Transaction Information, and a Transaction Statement, documenting prior ownership and certifying compliance with each change of ownership. The other option sets list unrelated documents, such as insurance forms, DEA controlled-substance forms, and licensing documents, that are not the DSCSA transaction documentation trio.

3. If an investigation into a suspect product concludes that the product is, in fact, legitimate, what should the pharmacy do?

Once an investigation determines suspect product is actually legitimate, it may be released from quarantine back into saleable inventory, while the pharmacy retains records documenting the investigation. Mandatory destruction (B) and FDA illegitimate-product notification (C) apply to confirmed illegitimate product, not product cleared of suspicion, and record retention (D) remains important regardless of outcome.

4. Approximately when did DSCSA's enhanced, interoperable electronic drug traceability requirements reach full effect after the law's phased implementation?

DSCSA was enacted in 2013 as Title II of the Drug Quality and Security Act, with requirements phased in over roughly a decade, reaching enhanced drug distribution security and interoperable traceability expectations around November 2023. A incorrectly claims no phase-in occurred, C predates the law's actual enactment, and B incorrectly denies that a timeline exists.

5. Which of the following best distinguishes DSCSA serialization and tracing requirements from DEA controlled substance ordering requirements, such as Form 222?

DSCSA is a broader traceability and anti-counterfeiting framework covering prescription drugs generally, distinct from the DEA's narrower Form 222 requirement, which specifically governs ordering Schedule I and II controlled substances. A incorrectly conflates the two distinct regulatory schemes, C wrongly narrows DSCSA's scope to match Form 222, and D incorrectly claims Form 222 covers all prescription drugs, which it does not.